<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sincalide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sincalide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sincalide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11574" href="/d/html/11574.html" rel="external">see "Sincalide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F221382"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kinevac</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868246"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kinevac</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F221390"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F221383"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c26468b1-bef5-4b93-be20-aa89f0b24a15">Barium meal transit time acceleration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Barium meal transit time acceleration: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.04 mcg/kg initiated once the barium meal is beyond the proximal jejunum; if movement of barium has not occurred in 30 minutes, a second dose of 0.04 mcg/kg may be administered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV infusion:</b> 0.12 mcg/kg over 30 minutes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f6fbd3d-12e5-4485-a714-0453eda57fba">Gallbladder contraction stimulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallbladder contraction stimulation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.02 mcg/kg; if satisfactory contraction does not occur in 15 minutes, a second dose of 0.04 mcg/kg may be given.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>
<b>infusion:</b> 0.12 mcg/kg over 50 minutes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19fc3109-42c1-4117-b194-dca377b325af">Pancreatic secretion stimulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic secretion stimulation: IV infusion:</b> 0.02 mcg/kg over 30 minutes; initiated 30 minutes after the start of the secretin infusion.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990752"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988134"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F221384"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F221369"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Abdominal distress (≥20%), abdominal pain (≥20%), nausea (≥20%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, anaphylactic shock, anaphylaxis, bowel urgency, bradycardia, diaphoresis, diarrhea, dizziness, dyspnea, facial numbness, flushing, headache, hypersensitivity reaction, hypertension, hypotension, loss of consciousness, pharyngeal edema, pruritus, seizure, skin rash, sneezing, syncope, urticaria, vomiting</p></div>
<div class="block coi drugH1Div" id="F2528945"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sincalide, sulfites, or any component of the formulation; intestinal obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): In patients where a fatty meal would be contraindicated, including: Acute abdomen; acute pancreatitis; acute cholecystitis; appendicitis; bleeding, penetrating, or perforating peptic ulcer; common bile duct obstruction; cystic duct obstruction; gallbladder empyema or infection; hollow viscous; mechanical GI tract obstruction; perforation; peritonitis; pyloric stenosis; small gallbladder stones.</p></div>
<div class="block war drugH1Div" id="F2528946"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal: IV injection may cause transient GI adverse effects (eg, nausea, vomiting, abdominal pain/cramping, dizziness, flushing). Administration via IV infusion may lessen risks of developing adverse GI effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious reactions, including anaphylaxis, have been reported during or within 1 hour following sincalide administration; monitor during and after infusion. Immediately discontinue therapy and initiate appropriate treatment for hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obstruction: Increased risk (minimal) of evacuating small gallstones into cystic duct or common bile duct and obstructing flow.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder response: Drugs known to stimulate or inhibit gallbladder motility or contractile response may interfere with response to sincalide. Consider temporary discontinuation of these drugs prior to sincalide administration when used for gallbladder contraction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Solution for injection contains sodium metabisulfite, which may cause allergic reactions in some individuals.</p></div>
<div class="block foc drugH1Div" id="F221373"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kinevac: 5 mcg (1 ea) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mcg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F221363"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323859"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Kinevac Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mcg (per each): $156.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Sincalide Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mcg (per each): $148.96 - $163.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868247"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kinevac: 5 mcg (1 ea) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mcg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F221375"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administration via infusion may help manage some adverse events or increase GI tolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">Contraction of gallbladder: Administer as an IV push over 30 to 60 seconds, or as an IV infusion mixed in 100 mL of NS over 50 minutes (2 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Pancreatic function: Administer as an IV infusion mixed in 30 mL of NS over 30 minutes (1 mL/minute) beginning 30 minutes after the initiation of secretin infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Accelerate barium transit through small bowel: Administer as an IV push over 30 to 60 seconds, or as an IV infusion mixed in 100 mL NS over 30 minutes. Administer dose after the barium meal is beyond the proximal jejunum.</p></div>
<div class="block use drugH1Div" id="F221374"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Barium meal transit time acceleration:</b> To accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gallbladder contraction stimulation:</b> To stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pancreatic secretion stimulation: </b>To stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology.</p></div>
<div class="block cyt drugH1Div" id="F13300044"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222940"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Drugs that Affect Gallbladder Function: May diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F2528942"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on limited human data (Silberstein 1994) and its effect on smooth muscle, use during pregnancy, including near term, should be avoided (may cause spontaneous abortion or premature labor).</p></div>
<div class="block brc drugH1Div" id="F16571175"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sincalide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F2528956"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reaction (during and within 1 hour of administration).</p></div>
<div class="block rer drugH1Div" id="F2528954"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Gallbladder size: ≥40% reduction considered a satisfactory contraction.</p></div>
<div class="block pha drugH1Div" id="F221366"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates contraction of the gallbladder; inhibits gastric emptying by causing pyloric contraction, and increases intestinal motility; stimulates pancreatic secretion; causes smooth muscle contraction</p></div>
<div class="block phk drugH1Div" id="F221377"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Onset of action: Contraction of the gallbladder: ~5 to 15 minutes </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58197642"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kinevac</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Kinevac</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kinevac</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Kinevac (sincalide) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; October 2023.</div>
</li>
<li>
<div class="reference">
                  Kinevac (sincalide) [product monograph]. Montreal, Quebec, Canada: Bracco Imaging Canada; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8115649">
<a name="8115649"></a>Silberstein EB, Marcus CS. Unreported side effect of sincalide. <i>Radiology</i>. 1994;190(3):902. doi: 10.1148/radiology.190.3.8115649.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sincalide-drug-information/abstract-text/8115649/pubmed" id="8115649" target="_blank">8115649</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sincalide [prescribing information]. Princeton, NJ: MAIA Pharmaceuticals Inc; October 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10266 Version 130.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
